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Abstract
In South Africa young women bear a disproportionate burden of HIV infection however, risk 
factors for HIV acquisition are not fully understood in this setting. In a cohort of 245 women, we 
used proportional hazard regression analysis to examine the association of demographic, clinical 
and behavioural characteristics with HIV acquisition. The overall HIV incidence rate (IR) was 
7.20 per 100 women years (wy), 95% Confidence Interval (CI) 4.50–9.80]. Women 18–24 years 
had the highest HIV incidence [IR 13.20 per 100 wy, 95% CI 6.59–23.62] and were almost three 
times more likely to acquire HIV compared to women 25 years and older [adjusted Hazard Ratio 
(aHR) 2.61, 95% CI 1.05–6.47]. Similarly, women in relationships with multiple sex partners had 
more than twice the risk of acquiring HIV when compared to women who had no partner or who 
had a husband or stable partner (aHR 2.47, 95% CI 0.98–6.26). HIV prevention programmes must 
address young women's vulnerability and sex partner reduction in this setting.
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Into the fourth decade of the Human Immunodeficiency Virus (HIV) epidemic, South Africa 
has an estimated 6.1 million people living with HIV and contributes 17% of the global HIV 
burden, yet accounts for only 0.7% of the world's population (1, 2). With the majority of 
infections heterosexually acquired, young women bear a disproportionate burden of HIV. 
Sentinel surveillance among pregnant women shows that in 1990, HIV prevalence was 0.7% 
and by 1998 increased exponentially to 22.8%, peaking at 30.2% in 2010 (3). Data from 
national population based surveys show similar trends with high HIV prevalence in young 
women compared to young men (4, 5). HIV prevalence peaked at 36.0% among women 
aged 30–34 years and at 28.8% among men in the 35–39 year–old age group (5). HIV 
prevalence in women aged 15–19 years was 5.6%, eight times higher than males in the same 
age group, and increased to 17.4% among women aged 20–24 years and 28.4% in the 25–29 
year age group (5). Within South Africa there is significant geographical variation in the 
distribution of HIV and the province of KwaZulu–Natal remains the worst affected. Whilst 
prevalence of HIV has been useful to understand the evolving epidemic, HIV incidence rate 
is a more sensitive measure to monitor the epidemic. Amongst rural and urban women the 
HIV incidence rates have been 6.5 and 6.4 per 100 women years (wy) respectively, and in 
young women <18 years 4.7 per 100 wy (6, 7). These data underscore the need to 
understand the risk factors contributing to these high HIV prevalence and incidence rates.
The key risk factors for HIV in the South African setting include a combination of 
structural, behavioural and biological factors. Poverty, labour migration, urbanisation, 
gender inequalities and gender–based violence contribute to an increased susceptibility to 
HIV (8, 9). At the individual level, being single, unemployed or not achieving a high school 
education increase vulnerability and predispose young women to HIV (5, 10, 11). High risk 
sexual behaviour such as engaging in multiple concurrent partnerships, transactional sex and 
age–disparate relationships, has contributed significantly to enhancing HIV risk and is 
exacerbated by the inability of women to negotiate condom use even in long–term 
partnerships (9, 12-15). Physiological changes of the genital tract as well as factors which 
affect the integrity of the genital tract epithelium such as sexually transmitted infections 
(STIs) and intra–vaginal insertion practices, either for cleansing or enhancing sex, may 
increase susceptibility to HIV by facilitating viral entry (9, 16-19). Recent data suggests that 
genital tract inflammation in women with symptomatic and asymptomatic STIs may 
upregulate HIV susceptible target cells at the mucosal level thereby aiding transmission 
(20). The association between hormonal contraception use, in particular progestogen–only 
injectable preparations, and HIV risk remains contentious as current biological and 
epidemiological evidence is limited (21, 22).
As the HIV epidemic evolves, it is important to understand the factors that contribute to 
vulnerability and risk so that the design of HIV prevention programmes are tailored taking 
these into account. In this prospective cohort study we explored factors associated with HIV 
acquisition in a generalised epidemic setting.
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Study Setting and Study Population
The Centre for the AIDS Programme of Research in South Africa (CAPRISA) initiated the 
CAPRISA 002 study to advance the understanding of HIV–1 subtype C acquisition, 
pathogenesis and disease progression. Between August 2004 and May 2005 volunteers from 
the city of Durban, KwaZulu–Natal, South Africa were recruited for study participation. 
Eligibility criteria and screening and enrolment procedures have been described (23). Briefly 
women 18 years and older, self–identifying as sex workers or having had at least three 
partners in the 3 months prior to recruitment, and testing HIV negative were eligible for 
study participation.
Study procedures
Volunteers were provided with verbal and written information about the study objectives 
and procedures after which written consent for screening procedures and for long– term 
storage of specimens were obtained. Women agreeing to participate in the study received 
pre and post–test counselling for HIV testing and risk reduction counselling and had blood 
samples collected for HIV antibody testing. Women testing HIV positive were referred to 
support services for ongoing care and psychosocial support. All women testing HIV 
antibody negative or indeterminate were enrolled until the study endpoint of HIV infection 
or for a period of 24 months.
At baseline, trained nurses administered questionnaires to all participants to obtain 
information regarding socio–demographic history, risk behaviour, knowledge about HIV 
and more direct questions related to sex work. A complete physical examination was 
undertaken at baseline and at each monthly follow up visit. Urine pregnancy testing was 
done if clinically indicated or upon request by a participant (23). Pelvic examination for 
genital sample collection was undertaken at baseline and at six monthly intervals. Blood 
specimen collection was done at baseline (safety monitoring tests, serological testing for 
STIs and long–term storage), at each monthly visit (HIV testing) and at each six–monthly 
visit (safety monitoring tests and serological testing for STIs).
Laboratory Evaluations
HIV testing was done using two rapid antibody tests using the Determine HIV–1 test 
(Abbott Diagnostics, Johannesburg, South Africa) and the Capillus HIV–1/HIV–2 test 
(Trinity Biotech, USA) followed by HIV–1 RNA polymerase chain reaction (PCR) testing 
using the Cobas AmpliScreen Multiprep HIV–1 test version 1.5 and the Cobas AmpliPrep/
Cobas Amplicor HIV–1 Monitor test version 1.5 (Roche Diagnostics, Branchburg, New 
Jersey, USA) if at least one rapid antibody test was negative (24). Confirmatory HIV ELISA 
testing was done on PCR positive samples (Enzynost anti HIV1/2 plus Dade Behring, 
Deerfield, Illinois, USA) (24). HIV infection as endpoint was based on a positive HIV–1 
antibody test with a previously documented negative HIV–1 antibody test; or the presence of 
HIV–1 RNA in the absence of HIV antibodies (23).
Naicker et al. Page 3













Safety monitoring tests comprised haematological and biochemical evaluations. Genital 
specimens were tested for Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas 
vaginalis, Mycoplasma genitalium and herpes simplex virus (HSV) type 2 using PCR and 
bacterial vaginosis (BV) was diagnosed on Gram–stained smears using Nugent's criteria 
(20). Syphilis [Becton Dickinson Macro– Vue RPR (rapid plasma reagin) card test, BD 
Diagnostic systems United States and Omega IMMUTREP TPHA (Treponema pallidum 
Hemaglutination Assay) test, Omega Diagnostics Group PLC], HSV infection 
(HerpeSelect–1 and HerpeSelect–2, Enzyme–linked immunosorbent assay, Focus 
Diagnostics, Cypress, CA) and hepatitis B (HBV) infection (Centaur XP, ADVIA Centaur 
XP Immunoassay System, SIEMENS AG, Germany) were diagnosed serologically.
Data Management
Demographic, behavioural, clinical and laboratory data were captured onto standardised 
case report forms (CRFs) which were coded with a participant identification number in order 
to maintain participant confidentiality. CRFs were faxed using the DataFax system (Clinical 
DataFax Sytems Inc., Ontario, Canada), with all data verified by data encoders for quality 
checks and stored in a secure study specific database.
Measures
HIV–1 infection was the main outcome measure. Baseline information on socio– 
demographic factors (age, number of dependents, educational level), behavioural factors 
(age at sexual debut, relationship status, frequency and type of sex acts, male and or female 
condom use [defined as condom use] at last sex act, contraception type, douching, alcohol 
and substance use prior to sex), sex for compensation (time period involved in sex work, age 
started sex work, days per week engaged in sex work, number of sites worked at, number of 
sex clients, short sessions or overnight stays per week with clients and condom use), clinical 
factors, including pregnancy and laboratory measures (full blood counts, liver function tests, 
electrolytes, vitamin B12, folate, iron, glucose, calcium, phosphate, CD4+, CD3+ and CD8+ 
cell counts and STIs), and knowledge questions on HIV prevention and transmission were 
obtained.
Statistical Analysis
Baseline data were summarised using descriptive statistics, with continuous variables 
reported as means and standard deviations or medians and interquartile ranges, while 
categorical variables are reported as percentages and actual numbers. Unadjusted and 
adjusted proportional hazards regression analysis was performed to assess the impact of 
socio–demographic factors, risk behaviour, sex for compensation and clinical factors on 
HIV acquisition. Estimated time of HIV infection was defined as the midpoint between the 
last negative HIV ELISA and the first positive HIV ELISA or 14 days prior to a positive 
HIV–1 RNA test if the HIV ELISA is negative on the same day (23). Time to HIV infection 
was calculated from the date of enrolment until the estimated time of HIV infection. 
Participants who remained HIV negative were censored at their last visit. Factors with a p– 
value of less than 0.2 in the unadjusted analysis were included in the adjusted model. Given 
the biological plausibility of anal sex and the risk for HIV acquisition, this variable was 
included in a multivariable model as was contraception type although current evidence is 
Naicker et al. Page 4













limited (25-28). Although some variables relating to sex work had a p–value of less than 0.2 
in the unadjusted analysis, these were not included in the adjusted model, because a large 
proportion of the cohort did not identify themselves as sex workers. The second 
multivariable model was restricted to women reporting sex for compensation.
P–values less than 0.05 were considered statistically significant. Analysis was performed 
using SAS software version 9.3 (SAS Institute Inc., Cary).
Ethics Approval
Ethics approval for the CAPRISA 002 study was obtained from the Universities of Natal 
(E013/04), Cape Town (025/2004) and Witwatersrand (MM040202). The ethical approval 
for the secondary analysis of data was granted from the Biomedical Research Ethics 
Committee, University of KwaZulu–Natal (BE 092/11) and permission to review data stored 
in the CAPRISA 002 database was approved through the CAPRISA data sharing policy.
Results
A total of 775 women were screened of whom 509 (65.7%) were ineligible for the following 
reasons: tested HIV positive (n=462; 59.6%), reported less than three sexual partners in the 
previous three months (n=22; 2.8%), were pregnant (n=16; 2.1%), planned to relocate (n=4; 
0.5%), younger than 18 years (n=3; 0.4%) or afraid of testing procedures (n=2; 0.3%) (23). 
Twenty–one (2.7%) women were eligible for study participation but did not return for 
enrolment and 245 (31.6%) were enrolled into the study.
After 390 wy of follow up, 28 women acquired HIV, yielding an incidence rate (IR) of 7.20 
per 100 wy [95% confidence interval (CI) 4.50–9.80]. Women aged 18–24 years had the 
highest HIV incidence (IR 13.20 per 100 wy, 95% CI 6.59–23.62) and among women 25 
years and older it was 4.58 per 100 wy (95% CI 2.50–7.68). Three women were excluded 
from any risk factor analyses as they were in the window period of HIV infection at study 
entry.
The baseline characteristics overall and of those acquiring HIV are shown in Table I. The 
mean age of 242 women was 34.3 years [standard deviation (SD) 10.47, range 18–58], 185 
(76.8%) women had one or more dependents and 156 women (64.5%) had an educational 
level which was above grade 8. The mean age at sexual debut was 17 years (SD 2.38, range 
12–26). Although a large proportion (191; 78.9%) self–identified themselves as sex workers, 
having spent a median of three years [interquartile range (IQR) 1.3–8.3] in sex work, only 
137 (56.6%) women reported being in a relationship with multiple partners at the time of the 
study.
Women who acquired HIV were approximately five years younger than those who remained 
HIV negative [t statistic (t)=2.20, p=0.029], reported being in relationships with multiple 
partners more frequently [Fisher's exact test hypergeometric probability (Fprob)=0.021, 
p=0.054] and had higher baseline serum vitamin B12 levels (t=-2.00, p=0.047).
Table II shows the socio–demographic, behavioural and biological variables associated with 
risk of HIV acquisition overall and by sex work. Younger women, aged 18–24 years were 
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almost three times more likely to acquire HIV compared to women 25 years and older 
[Hazard Ratio (HR) 2.85, 95% CI 1.29–6.28; Chi-square test statistic (χ2)=6.73; p=0.010] 
and similarly women reporting many partners were at almost three times greater risk of HIV 
acquisition (HR 2.61, 95% CI 1.04–6.52; χ2=4.18; p=0.041). A higher educational level, 
above grade 8, was weakly associated with increased risk for HIV (HR 2.45, 95% CI 0.92–
6.52; χ2=3.21; p=0.073), but no significant associations were found for HIV risk and 
engaging in anal sex (HR 1.49, 95% CI 0.68–3.29; χ2=0.99; p=0.321) or age at sexual debut 
(HR 0.88, 95% CI 0.73–1.06; χ2=1.88; p=0.170).
Among women reporting sex for compensation, HIV risk remained three–fold higher among 
18–24 year–old women (HR 3.27, 95% CI 1.29–8.30; χ2=6.24; p=0.013) and ten–fold 
higher among those reporting many partners (HR 10.32, 95% CI 1.37–77.55; χ2=5.15; 
p=0.023). Weak associations were found between increased HIV risk and every additional 
overnight stay per week with clients (HR 1.33, 95% CI 0.94–1.88; χ2=2.61; p=0.106) and 
reduced risk for every additional year spent in sex work (HR 0.93, 95% CI 0.85–1.02; 
χ2=2.34; p=0.126).
In the final multivariable model, young age remained significant for HIV risk (HR 2.61, 
95% CI 1.05– 6.47; χ2=4.27; p=0.039).
Discussion
In this study young age and having multiple sex partners were associated with risk for HIV 
acquisition. Despite the introduction of HIV prevention and treatment programmes, the 
overall HIV incidence rate of 7.20 per 100 wy, and 13.20 per 100 wy among women aged 
18–24 years remains unacceptably high (23). South Africa and many southern African 
countries continue to experience similar high HIV incidence rates. Longitudinal studies 
among women in South Africa have shown HIV incidence rates of 6.6, 8.5 and 6.5 per 100 
wy particularly amongst young women in the province of KwaZulu–Natal (6, 10, 29). 
Among pregnant women from the same region, HIV incidence was 10.7 per 100 wy (30). In 
Malawi and Zimbabwe, among women recruited from postnatal or family planning clinics, 
the HIV incidence rates were 4.20, 4.86 and 4.78 per 100 wy in Lilongwe, Blantyre and 
Harare respectively (31). Overall, the highest incidence rate of 5.78 per 100 wy was among 
young women <25 years, whilst in Rwanda, among antenatal clinic attendees HIV incidence 
was 10.5 per 100 wy among women < 20 years (31, 32). These studies demonstrate young 
women's vulnerability and greater risk of acquiring HIV compared to older women. Our 
study shows that young age carries a three–fold greater risk of HIV acquisition.
The importance of measuring HIV incidence is key to understanding the dynamics of HIV 
disease to shape and modify effective responses. The persistence of high HIV incidence 
rates and the vulnerability of young women is incompletely elucidated in this setting. Recent 
studies have shown that residing in urban informal settlements, being unmarried or 
unemployed was associated with higher HIV incidence highlighting the underlying 
structural and social factors driving the epidemic (5, 10). Although common in this setting, 
high risk behaviours such as engaging in age-disparate relationships, was not found to 
predict HIV risk in a population-based study and is less likely to contribute to high HIV 
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incidence in young women (33). Sexually transmitted infections are known to contribute to 
HIV risk in women in this region and ongoing research into the immunology of the female 
genital tract may provide further insight into the biological susceptibility to HIV infection, 
particularly in young women (10, 20).
Although the vulnerability of young women is well recognised in this setting, risk for HIV is 
often underestimated since the perceived risk of HIV remains low (5). South Africa's 
epidemic is generalised with HIV prevalence at an unprecedented high level, in excess of 
15% in the adult population, and new infection rates around 2% per year (5, 34). However, 
the majority of HIV– infected individuals are unaware of their HIV status, and this remains 
a barrier for both treatment access and prevention and helps sustain the epidemic. Poor 
knowledge of HIV transmission and limited access to and availability of health care services 
further promotes risk (5).
Our study demonstrates that women in relationships with multiple partners were more likely 
to acquire HIV. While multiple concurrent partnerships is recognised as a key driver of the 
epidemic in the Southern African region, the total number of lifetime partners has been 
found to be a significant predictor of HIV risk (12, 35). A meta–analysis of 68 studies from 
sub–Saharan Africa assessing risk factors for HIV acquisition reported that the number of 
lifetime partners increased the risk of HIV by almost four–fold [Odds Ratio (OR) 3.64, 95% 
CI 2.87–4.62] (35). In an urban mining community in Carletonville risk for HIV was almost 
five–fold higher in women reporting two or more lifetime partners (OR 4.88, 95% CI 3.01–
7.89) (36). This risk was almost double for women reporting more than one partner three 
months prior to enrolment into HIV prevention intervention studies (adjusted OR 1.78, 95% 
CI 1.11–2.85) and similar for young women 15–24 years (OR 2.0, 95% CI 1.1–3.7) 
participating in the national household survey of South African youth, reporting more than 
one lifetime partner (4, 37).
In this setting unemployment levels remain high and resources are constrained (9, 38). 
Marriage is also uncommon in this setting, leading to instability of relationships (9). 
Transactional sex, which may range from serial monogamous relationships to occasional 
exchange of sex for money or goods, or to employment as a sex worker, provides a means of 
survival for women and their dependents, resulting in women engaging in multiple 
partnerships, either sequential or concurrent, in order to meet their basic needs (8, 9). Hence, 
emphasis and efforts on monogamy and multiple partner reduction cannot stand alone. The 
integration of structural approaches into current HIV policy, which address the socio-
economic needs of women; and which create an environment of equal opportunities and 
rights, is crucial if behavioural and biomedical prevention efforts are to succeed. 
Nonetheless, rigorously including HIV counselling and testing (HCT) across all levels is 
important and key to knowledge of HIV status. HCT is especially important to help people 
learn their own and their partners’ status so as to reduce HIV risk. Furthermore, repeat HCT 
must be promoted in hyperendemic regions.
The use of hormonal contraception was not found to be associated with HIV acquisition. 
Results from several studies exploring the use of hormonal contraception increasing the risk 
of HIV acquisition remain inconsistent (21, 22, 27, 39). Major limitations of these studies 
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have been the failure to test the hypotheses through robust study designs. Earlier studies 
showed some signals of an association between hormonal contraception and HIV acquisition 
(27). Similarly intra–vaginal insertion practices and pregnancy were not associated with 
HIV risk, though the outcome may be limited by the small sample size.
Whilst elevated serum vitamin B12 levels was associated with HIV acquisition, its causal 
role requires further exploration. Recent evidence from critically ill elderly medical patients 
suggests that elevated serum vitamin B12 levels are associated with increased mortality (40, 
41). Although increased levels have been associated with systemic inflammatory markers, 
its role in mediating HIV risk remains unclear (40). While genital tract inflammation 
associated with HIV risk in this cohort has been reported, the role of vitamin B12 as a 
marker of systemic inflammation and HIV risk requires further evaluation (20).
The major strength of the study was the prospective cohort study design which allowed 
assessment of risk factors prior to HIV acquisition, however, there are several limitations as 
well. Firstly, participants had monthly study visits with risk reduction counselling, male and 
female condom provision, HIV testing with interviewer administered questionnaires; it is 
therefore possible that participants could have provided socially desirable responses given 
the sensitive nature of the sexual risk behaviour questions which could have biased the 
associations. Furthermore, given the wide age range of this cohort (18–58 years), it was 
difficult to adequately assess some risk behaviours which may be age dependent. Ideally, it 
would be important to follow up behaviour in those women who remained HIV negative to 
assess HIV risk over time. Secondly, the small sample size of the study is an important 
limitation, impacting on the precision of the study findings, therefore the particularly large 
confidences intervals around some of the point estimates. This may have also limited our 
ability to demonstrate stronger associations with some variables. Thirdly, the recruitment of 
high risk women limits the generalizability of the study findings as these may not be 
representative of women from elsewhere in the province. Finally, as the study excluded 
women younger than 18 years, it was not possible to measure HIV incidence and risk factors 
in this young age group in whom HIV incidence is high (7). Whilst there are ethical 
challenges in conducting research in adolescents, it is important that young people, 
especially girls are included into research studies in order to better understand the high rates 
of HIV acquisition (7, 42).
In conclusion, the findings of this study confirm that young women continue to bear the 
brunt of the HIV epidemic in this region. It is important that as transmission dynamics 
change over time, especially in hyperendemic settings, investments towards large–scale, 
fundamental changes in behaviour, social practices and community norms, address young 
women's vulnerability to HIV.
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Table I
Baseline socio–demographic, behavioural and biological characteristics of women, overall and by HIV status, 
Durban, South Africa, 2004/2007







Age in years (Mean, ±SD) 34.3 (10.47) 30.0 (10.37) 34.8 (10.39) t=2.20 0.029
Age group (in years) % (n)
    18–24 26.54% (64) 44.0% (11) 24.4% (53) Fprob=0.023 0.053
    ≥ 25 73.6% (178) 56.0% (14) 75.6% (164)
Number of dependents % (n)
    0 23.2% (56) 16.0% (4) 24.1% (52) Fprob=0.143 0.460
    ≥ 1 76.8% (185) 84% (21) 75.9% (164)
Educational level % (n)
    ≤Grade 8 35.5% (86) 20.0% (5) 37.3% (81) Fprob=0.042 0.121
    > Grade 8 64.5% (156) 80.0% (20) 62.7% (136)
Risk behaviour
Age in years at sexual debut (Mean, 
±SD)
17.0 (2.38) 16.5 (1.76) 17.1 (2.44) t=1.18 0.239
Relationship status % (n)
    No partner or Stable/Married partner 43.2% (104) 24.0% (6) 45.4% (98) Fprob=0.021 0.054
    Many partners 56.6% (137) 76.0% (19) 54.4% (118)
Mean sex acts per month (±SD) 10.3 (6.78) 10.3 (5.03) 10.3 (6.97) t=−0.01 0.994
Type of sex act % (n)
    Ever had vaginal sex 100% (242) 100% (25) 100% (217) – –
    Ever had anal sex 34.6% (83) 44.0% (11) 33.5% (72) Fprob=0.100 0.374
    Ever had oral sex 25.3% (61) 24.0% (6) 25.5% (55) Fprob=0.192 1.000
Condom use at last sex act % (n)
    Yes 58.7% (142) 64.0% (16) 58.1% (126) Fprob=0.147 0.670
    No 41.3% (100) 36.0% (9) 41.9% (91)
Any contraception % (n) 79.7% (192) 68.0% (17) 81.0% (175) Fprob=0.064 0.185
Contraception type % (n)
    Condom only 41.5% (100) 36.0% (9) 42.1% (91) Fprob=0.030 0.808
    Hormonal 30.7% (74) 32.0% (8) 30.5 (66)
    None/Other
b 27.8% (67) 32.0% (8) 27.2% (59)
Douching after sex % (n) 9.5% (23) 4.0% (1) 10.2% (22) Fprob=0.210 0.483
Sex after alcohol or substance use % 
(n)
    Yes 26.9% (65) 20.0% (5) 27.7% (60) Fprob=0.144 0.484
    No 73.1% (177) 80.0% (20) 72.4% (157)
Sex for compensation
Self-reported sex workers % (n) 78.9% (191) 72.0% (18) 79.7% (173) Fprob=0.129 0.436
Years in sex work (Median, IQR) 3.0 (1.3 – 8.3) 2.5 (1.0 – 7.0) 3.0 (1.3 – 9.0) Z=−1.36 0.179
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Age at start of sex work (Mean, ±SD) 28.2 (9.02) 27.2 (10.16) 28.3 (8.92) t=0.49 0.625
Days per week perform sex work 
(Mean, ±SD)
2.9 (1.40) 2.9 (1.55) 2.9 (1.39) t=−0.21 0.835
Sites worked per year (Mean, ±SD) 2.6 (1.30) 2.8 (0.86) 2.6 (1.33) t=−1.08 0.291
Clients per day (Mean, ±SD) 2.5 (1.19) 2.6 (1.24) 2.5 (1.19) t=−0.36 0.722
Clients in the past week (Mean, ±SD) 3.1 (3.83) 2.4 (2.53) 3.1 (3.94) t=1.01 0.323
Short sessions per week (Mean, ±SD) 4.2 (4.05) 3.6 (4.68) 4.3 (3.99) t=0.63 0.527
Overnight stays per week (Mean, ±SD) 1.1 (1.20) 1.4 (1.34) 1.0 (1.19) t=−1.46 0.147
Condom use in the last month % (n)
    Always 38.2% (73) 27.8% (5) 39.3% (68) Fprob=0.033 0.650
    Sometimes 42.9% (82) 50.0% (9) 42.2% (73)
    Never 18.9% (36) 22.2% (4) 18.5% (32)
HIV knowledge
How safe is anal sex compared to peno–vaginal sex? % (n)
    Same or more risk 62.8% (152) 56.0% (14) 63.6% (138) Fprob=0.002 0.278
    Less risk or don't know 37.2% (90) 44.0% (11) 36.4% (79)
How safe is oral sex compared to peno–vaginal sex? % (n)
    Same or more risk 71.8% (173) 68.0% (17) 72.2% (156) Fprob=0.163 0.644
    Less risk or don't know 28.2% (68) 32% (8) 27.8 (60)
If you have an STI are you more likely to get HIV? % (n)
    Yes 71.1% (172) 80.0% (20) 70.1% (152) Fprob=0.085 0.665
    No 1.7% (4) 0.0% (0) 1.8% (4)
    Only sometimes/unsure 27.3% (66) 20.0% (5) 28.1% (61)
Do you think HIV can be treated? % 
(n)
    Yes 95.0% (230) 96.0% (24) 94.9% (206) Fprob=0.159 0.516
    No 2.1% (5) 4.0% (1) 1.8% (4)
    Unsure 2.9% (7) 0.0% (0) 3.2% (7)
Clinical evaluation
Ever pregnant prior to HIV % (n)
    Yes 10.3% (25) 12.0% (3) 10.1% (22) Fprob=0.244 0.730
    No 89.7% (217) 88.0% (22) 89.9% (195)
Laboratory parameters
Haemoglobin g/dL (Mean, ±SD) 12.7 (1.29) 12.8 (1.43) 12.7 (1.27) t=−0.51 0.613
Eosinophils 1 × 109/L (Mean, ±SD) 0.2 (0.24) 0.3 (0.25) 0.2 (0.24) t=−0.81 0.420
Albumin g/L(Mean, ±SD) 44.7 (3.57) 44.8 (3.32) 44.7 (3.60) t=−0.02 0.981
Vitamin B12 pg/mL (Mean, ± SD) 291.0 (93.14) 327.6 (112.19) 287.0 (90.25) t=−2.00 0.047
Folate ng/mL (Mean, ±SD) 22.4 (8.45) 20.8 (8.54) 22.6 (8.45) t=0.94 0.346
Serum iron μmol/L (Mean, ±SD) 12.3 (6.41) 12.1 (5.36) 12.3 (6.53) t=0.16 0.877
Random glucose mmol/L (Mean, ±SD) 5.2 (2.02) 4.7 (0.85) 5.3 (2.11) t=2.72 0.008
Sodium mmol/L (Mean, ±SD) 137.1 (2.22) 138.2 (2.08) 137.0 (2.21) t=−2.66 0.008
Potassium mmol/L (Mean, ± SD) 4.0 (0.32) 4.1 (0.41) 4.0 (0.32) t=−0.35 0.730
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Chloride mmol/L (Mean, ±SD) 103.0 (2.55) 103.9 (1.98) 102.9 (2.59) t=−1.93 0.054
Calcium mmol/L (Mean, ±SD) 2.4 (0.12) 2.4 (0.09) 2.4 (0.12) t=−0.67 0.501
Phosphate mmol/L (Mean, ±SD) 1.1 (0.18) 1.1 (0.17) 1.0 (0.18) t=−1.43 0.155
HIV negative CD4+ count cells/μl 
(Median, IQR)
888 (742 – 1132) 969 (855 – 1068) 878 (738 – 1132) Z=0.76 0.446
HIV negative CD3+ count cells/μl 
(Median, IQR)
1493 (1202 – 1839) 1522 (1324–1857) 1486 (1197 – 1822) Z=0.58 0.564
HIV negative CD8+ count cells/μl 
(Median, IQR)
517 (402 – 688) 500 (420–760) 520 (402–680) Z=−0.04 0.966




31.3% (75/240) 44.0% (11) 29.8% (64/217) Fprob=0.063 0.172
a
Test statistic are: t=t-tests or Z=Wilcoxon Rank Sums (Normal Approximation), for continuous variables; Fprob=Fisher's exact test 
hypergeometric probability, for categorical data
b
Female sterilisation or rhythm/calendar method
c
Any STI present if participant tested positive for syphilis antibodies or Trichomonasvaginalis, Neisseria gonorrhoeae, Mycoplasma genitalium, 
Chlamydia trachomatis or herpes simplex virus (HSV) type II (PCR)
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